From Glucose Control to Liver Care: Semaglutide Becomes China's First GLP-1 Approved for MASH

A Boundary Crossed: GLP-1 Enters Hepatology

    On 10 September, China's National Medical Products Administration (NMPA) approved semaglutide injection (Wegovy®) for metabolic dysfunction-associated steatohepatitis (MASH), in non-cirrhotic adults with moderate to advanced liver fibrosis — specifically stage F2–F3. With this, semaglutide becomes the first GLP-1 receptor agonist approved in China for the treatment of MASH.

    Semaglutide first became widely known for lowering blood glucose and driving weight loss. This approval pushes its clinical use beyond those two traditional metabolic measures and into the liver — an organ previously thought to have little to do with GLP-1 biology. This is more than "one more indication." It reflects a fundamental shift in how GLP-1 therapies are positioned in metabolic disease. For years, clinicians understood these agents primarily as glucose-lowering or weight-reduction tools. Today a growing body of research is focused on their effect on cardiovascular, kidney, and liver outcomes.

Why the Liver Matters: A Long-Underserved Battlefield

    To appreciate the breakthrough, consider how difficult MASH has been to treat.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, insulin resistance, and type 2 diabetes. Some patients progress from simple fat accumulation to MASH, accompanied by varying degrees of fibrosis. What determines long-term risk is not the mere presence of fatty liver, but whether inflammation and fibrosis keep progressing — as fibrosis advances, the risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma rises. This is why F2–F3 has become the priority population for drug development. At this stage, fibrosis is clearly established but cirrhosis has not yet developed, leaving the widest theoretical window for intervention.

    The problem is that treatment options have been limited. Lifestyle modification has long been the foundation, but for patients with moderate-to-advanced fibrosis, diet, exercise, and weight loss alone often fail to produce stable disease improvement. That unmet need is exactly where semaglutide now lands.

Where the Evidence Stands: Two Histological Endpoints

    Approval is based on Part 1 of the phase 3 ESSENCE trial, which enrolled 1,197 biopsy-confirmed MASH patients with F2 or F3 fibrosis. The study assessed whether semaglutide could achieve MASH resolution and fibrosis improvement, respectively, without worsening the other liver parameter.

These endpoints matter because MASH drugs cannot rest on lower liver enzymes or reduced body weight alone. Regulators and clinicians require proof that a drug actually alters inflammation and fibrosis within liver tissue.

    Semaglutide delivered on both counts: more patients achieved resolution of inflammation, and a meaningful subset showed fibrosis improvement. For a GLP-1 originally positioned for metabolic disease, this provides direct evidence supporting its entry into hepatology.

From "Weight-Loss Drug" to Metabolic Platform

    For years, the GLP-1 conversation revolved around two words: diabetes and weight loss. As large outcome trials have read out, the clinical picture has grown more complex.

Semaglutide already carries evidence in cardiovascular outcomes and kidney disease. The MASH indication adds the liver. For Novo Nordisk, this extends the product lifecycle. For the GLP-1 category, it signals that competition is no longer about who reduces more weight — the real contest is who can cover more obesity-related complications and back it with robust hard-endpoint and long-term outcome data.

    Obesity patients rarely have only a weight problem. Many simultaneously live with diabetes, fatty liver, cardiovascular disease, and sleep apnea. A drug that improves several risk factors at once changes both its clinical value and the logic of reimbursement. The inclusion of MASH in semaglutide's label is a direct expression of that trend.